In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glycoform Ltd.

Executive Summary

Glycoform Ltd. aims to leverage the pioneering glyco-chemistry research of its Oxford University founders to develop targeted drug delivery systems and to improve the safety and efficacy of protein therapeutics, including monoclonal antibodies, by taking advantage of the way specific oligosaccharides, or sugar motifs, can affect the properties of the proteins they decorate.

You may also be interested in...

Glycobiology's Second Wave

New technologies to characterize and manipulate carbohydrate chemistries and the glycosylation of proteins are spawning viable business models that address what scientists have long known: the sugar coating of proteins and cells is not decorative.

Glycart Biotechnology AG

Glycart Biotechnology is a Zurich-based start-up that aims to generate antibodies with improved glycosylation characteristics to increase therapeutic potency. The firm's GlycoMAb technology can be applied to customers own cellular production systems to generate more effective versions of existing or experimental antibody therapeutics.

Biogenerics: Threat or Opportunity?

The EMEA's recommended approval of Novartis' generic growth hormone Omnitrop may pave the way for further biogeneric approvals in Europe. But high entry costs and questionable demand mean straight copies of biologics may not prove the most threatening to branded players/the most valuable market. The real battle will likely be around improved biologics: longer-lasting, safer and more efficacious versions. This widens the playing field, but places branded players with the advantage-for now.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts